SCHEMBL7906217

SCHEMBL7906217

CCN1CCN(Cc2nc3c(O)c(Cl)cc(Cl)c3c(=O)n2CC2CC2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.39
ALOX15 P16050 1/20 0.39
ALDH1A1 P00352 8/20 0.37
HSD17B10 Q99714 3/20 0.37
POLB P06746 3/20 0.37
GAA P10253 3/20 0.37
KDM4E B2RXH2 2/20 0.37
GLA P06280 1/20 0.37
HPGD P15428 1/20 0.37
CASP1 P29466 1/20 0.37
CASP7 P55210 1/20 0.37
ESR2 Q92731 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36
TSHR P16473 1/20 0.35
CNR2 P34972 2/20 0.35
MAPT P10636 2/20 0.34
HTT P42858 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7904228 0.91 NPC1 (0.39) ALOX15ALDH1A1HSD17B10POLBGAA
SCHEMBL7903324 0.90 NPC1 (0.41) ALOX15ALDH1A1HSD17B10POLBGAA
SCHEMBL7896788 0.88 ALDH1A1 (0.43) ALDH1A1HSD17B10POLBGAAKDM4E
SCHEMBL7904673 0.84 MEN1 (0.39) ALOX15ALDH1A1HSD17B10POLBGAA
SCHEMBL7897273 0.83 HSD17B13 (0.36) ALDH1A1HSD17B10POLBGAAKDM4E
SCHEMBL7899042 0.83 HSD17B13 (0.35) ALDH1A1HSD17B10GAAKDM4EGLA
SCHEMBL3467749 0.82 HSD17B13 (0.37) ALDH1A1POLBSMN1; SMN2LMNAHSD17B13
SCHEMBL7897177 0.82 HSD17B13 (0.35) ALDH1A1NPSR1CNR2HTTLMNA
SCHEMBL7897320 0.82 NPC1 (0.43) ALOX15ALDH1A1HSD17B10POLBGAA
SCHEMBL7897324 0.82 CRHR1 (0.33) CNR2HSD17B13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2379510-B1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LTD (AU) 2016-10-26 EP disclosed
US-20150359796-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2015-12-17 US disclosed
US-20150359796-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2015-12-17 US disclosed
US-9145375-B2 Quinazolinone compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2015-09-29 US disclosed
US-9145375-B2 Quinazolinone compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2015-09-29 US disclosed
US-20150025072-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2015-01-22 US disclosed
US-20150025072-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2015-01-22 US disclosed
US-8889695-B2 Quinazolinone compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2014-11-18 US disclosed
US-8889695-B2 Quinazolinone compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2014-11-18 US disclosed
US-20120040980-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2012-02-16 US disclosed
US-20120040980-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2012-02-16 US disclosed
WO-2010071944-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150359796-A1 QUINAZOLINONE COMPOUNDS PARK7, SNCA, NDUFV2 TP53 2687/4885ALOX15 2016/4885ALDH1A1 866/4885
US-20150025072-A1 QUINAZOLINONE COMPOUNDS PARK7, SNCA, NQO2 TP53 2893/4885ALOX15 2030/4885ALDH1A1 937/4885
US-20120040980-A1 QUINAZOLINONE COMPOUNDS PARK7, SNCA, NQO2 TP53 2893/4885ALOX15 2030/4885ALDH1A1 937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.